Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

NCT04501874
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
EMB-001, EMB-001 Placebo
Drug
Lead sponsor
Embera NeuroTherapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parameters of Exercise to Prevent Osteoporosis

NCT04063813
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Experimental: 40 minute up trial, Experimental: 40 minute down trial, Experimental: Two 20 minute up trials, Experimental: Two 20 min down trials, Active Comparator: Sedentary trial
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

NCT00483756
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
37
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 25, 2026, 1:23 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Study of Orofacial Pain and PropRANOlol

NCT02437383
View directory record Official record
Conditions
Temporomandibular Disorders
Interventions
Propranolol ER, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Gainesville, Florida • Buffalo, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

NCT06117280
View directory record Official record
Conditions
Energy, Focus, Caffeine Withdrawal
Interventions
Paraxanthine 200 mg, Paraxanthine 300 mg, Placebo
Other
Lead sponsor
Iovate Health Sciences International Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Hip Activation Compared to Hip Plus Balance Training on the Forward-Step-Down Test

NCT06298903
View directory record Official record
Conditions
Control of Frontal Plane Biomechanics, Patellofemoral Pain Syndrome
Interventions
Hip Activation, Hip activation + Single leg balance
Other
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 25, 2026, 1:23 PM EDT
Recruiting Not applicable Interventional

Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person vs. ONline

NCT06432790
View directory record Official record
Conditions
Overweight, Childhood, Obesity, Childhood, Asthma in Children
Interventions
CHAMPION
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

NCT04510597
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cytoreductive Nephrectomy, Active Comparator
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
387
States / cities
Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment

NCT04364191
View directory record Official record
Conditions
Mild Cognitive Impairment, Insomnia
Interventions
Multicomponent Behavioral Sleep Intervention for Insomnia, Active Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 25, 2026, 1:23 PM EDT
Withdrawn Early Phase 1 Interventional

D-cycloserine Augmented Treatment for Youth With Tic Disorders

NCT04357951
View directory record Official record
Conditions
Tourette Syndrome
Interventions
d-cycloserine, Placebo pill, Behavior Therapy
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 25, 2026, 1:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Essential Oil Inhalation and Acute Stress Response in Healthy Adults

NCT07473544
View directory record Official record
Conditions
Psychological Stress
Interventions
Essential Oil Inhalation, Placebo Aroma Stick
Other
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 45 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 1:23 PM EDT
Completed No phase listed Observational

VeClose Five Year Follow-Up Extension Study

NCT03455699
View directory record Official record
Conditions
Great Saphenous Vein (GSV) With Venous Reflux Disease
Interventions
VenaSeal SCS, ClosureFast Radiofrequency Ablation (RFA), Roll-In (VenaSeal SCS)
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
21 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Greenwood Village, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

NCT03119363
View directory record Official record
Conditions
Multiple Myeloma, Fatigue
Interventions
AYO light glasses (Experimental), AYO light glasses (Comparator)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 4 Interventional

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

NCT00630019
View directory record Official record
Conditions
Cataract
Interventions
1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin hydrochloride ophthalmic solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

NCT03198507
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
RHB-105, Active Comparator
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
55
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

NCT06579105
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes

NCT03329027
View directory record Official record
Conditions
Constipation
Interventions
Vibrating Capsule, Sham capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Canoga Park, California • Albuquerque, New Mexico • Willoughby, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

NCT05648110
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 1:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688
View directory record Official record
Conditions
Healthy Aging
Interventions
NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 25, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Creating Live Interactions to Mitigate Barriers

NCT03317769
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 25, 2026, 1:23 PM EDT